---
document_datetime: 2025-12-02 13:17:54
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pregabalin-sandoz-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: pregabalin-sandoz-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.0086485
conversion_datetime: 2025-12-25 04:06:50.469805
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Pregabalin Sandoz

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Article 61(3) /      | - Notification acc. Article 61(3) - Accepted | 02/12/2025                          |                                             | PL                               |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000313464                         | Update of the package leaflet with revised contact details of local representatives.                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |     |                                                                                                                                                     |
|------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000313836    | B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted                                                                                                                                                                                                                                                                                                                                                                                             | 27/11/2025 | N/A |                                                                                                                                                     |
| Variation type IA_IN / EMA/VR/0000309265 | B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.3 New certificate from a new manufacturer (replacement or addition) - Accepted                                                                                                                                                                                                                                                                                                                                 | 30/10/2025 | N/A |                                                                                                                                                     |
| Variation type IB / EMA/VR/0000273334    | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted To align the RMP to the currently approved RMP if the reference product, e.g removing the important identified risk of \"Abuse and drug dependence\". | 18/09/2025 | N/A | To align the RMP to the currently approved RMP if the reference product, e.g removing the important identified risk of \"Abuse and drug dependence\". |

<div style=\"page-break-after: always\"></div>

| Variation type IA_IN / EMA/VR/0000252648   | B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.1 Not including batch control/testing - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 18/02/2025   |     | Annex II and PL   |                   |
|--------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----|-------------------|-------------------|
| Variation type IA /                        | B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved manufacturer - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 21/01/2025   | N/A |                   | EMA/VR/0000245431 |
| Variation type IB /                        | This was an application for a group of variations. C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted A. ADMINISTRATIVE CHANGES - A.6 Change in ATC Code / ATC Vet Code - Accepted C.I.2.a - To update section 4.4 of the SmPC in order to add information on potential abuse in recreational drug users, following assessment of the same change in the reference product. A.6 - To change the ATC code from N03AX16 to N02BF02. | 21/11/2024   |     | SmPC and PL       | EMA/VR/0000231572 |

<div style=\"page-break-after: always\"></div>

|                                       | Furthermore, the Marketing Authorisation Holder has taken the opportunity to update the local representative details for Romania and Slovakia.                                                                                                                                                                                       |            |            |             |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| Article 61(3) / EMA/N/0000224521      | - Notification acc. Article 61(3) - Accepted Update of the package leaflet with revised contact details of local representatives and deletion of 'United Kingdom (Northern Ireland)' from the list of local representatives in line with the QRD template v10.4.                                                                     | 04/09/2024 |            | PL          |
| Variation type IA / EMA/VR/0000174983 | A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted    | 24/04/2024 | N/A        |             |
| Variation type IB / EMA/VR/0000168879 | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted | 07/03/2024 | 29/05/2024 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

|                                          | To update the SmPC sections 4.4 and 4.8 and section 3 in the PIL with 'suicidal ideation' as part of the observed withdrawal symptoms.                                                     |            |     |
|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA_IN / EMA/VR/0000168275 | B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.3 New certificate from a new manufacturer (replacement or addition) - Accepted | 20/02/2024 | N/A |